Jugoremedija put up for sale again – Application deadline February 19
Comments
(Photo: Pavel Kubarkov/shutterstock.com)
The factory has been evaluated at close to RSD 3.9 billion. The buyout of the documentation will cost interested buyers RSD 500,000, and the mandatory deposit amounts to RSD 777.33 million.
Jugoremedija’s property includes the factory’s industrial complex, the accompanying equipment, an apartment, 28 vehicles, inventory… The sale also includes intellectual property – 21 medical drug trademarks, as well as the lawsuit at the Commercial Court of Zrenjanin over the return of permits for the sale of 22 medical drugs.
Nine trademarked medical drugs, as well as 12 medical products – generic drugs for which Jugoremedija owns the complete technological procedure, are also being sold.
The offers are submitted until February 19, at 11:45 am, and the public opening of the bids will take place only 15 minutes later at the factory’s premises.
Let us remind that the attempt to sell the factory this October was cancelled following the complaint made by the Board of Creditors. The Commercial Court of Zrenjanin upheld the complaint and the public bidding scheduled for October 16, 2017, was cancelled.
Companies:
Jugoremedija a.d. Zrenjanin
Tags:
Jugoremedija
sale of Jugoremedija
Board of Creditors of Jugoremedija
pharmaceutical facilities in Zrenjanin
production licenses of Jugoremedija
medical drug production
production of medicaments
medical drug
medical drugs
medical drug plant
production of medical drugs
production of pharmaceutical products
pharmaceutical products
Radovan Savic
Comments
Your comment
Most Important News
Full information is available only to commercial users-subscribers and it is necessary to log in.
Follow the news, tenders, grants, legal regulations and reports on our portal.
Registracija na eKapiji vam omogućava pristup potpunim informacijama i dnevnom biltenu
Naš dnevni ekonomski bilten će stizati na vašu mejl adresu krajem svakog radnog dana. Bilteni su personalizovani prema interesovanjima svakog korisnika zasebno,
uz konsultacije sa našim ekspertima.